Technology company Tempus AI Inc (NASDAQ: TEM) and Medtronic on Wednesday announced results from the ALERT trial, demonstrating that AI-driven electronic health record notifications significantly improve the evaluation and treatment of patients with valvular heart disease.

This multicentre, cluster-randomised study - presented at the American College of Cardiology's 75th Annual Scientific Session & Expo - evaluated an automated notification system designed to address the undertreatment of aortic stenosis and mitral regurgitation. The trial leveraged the Tempus Next platform, which uses natural language processing to extract echocardiogram data and deliver real-time, guideline-based alerts to clinicians.

The study included 765 clinicians and 2,016 echocardiograms across five US health systems and 35 hospitals. It met its primary endpoint, with patients in the alert group 27% more likely to receive specialist evaluation or valve intervention compared with usual care (win ratio 1.27; P = .007). The system also drove a 40% relative increase in valve procedures and a 27% rise in multidisciplinary heart team evaluations within 90 days.

These findings highlight the potential of AI-enabled clinical decision support to reduce treatment delays and improve outcomes in conditions associated with high mortality if left untreated. The trial also demonstrated the technology's capacity to address disparities in care, supporting more consistent intervention across diverse patient populations.

Tempus AI said the device-agnostic system is designed to standardise care delivery without requiring the use of specific Medtronic products, enabling broader adoption across healthcare settings.